Development of drugs for celiac disease: Review of endpoints for Phase 2 and 3 trials

Klaus Gottlieb, Jill Dawson, Fez Hussain, Joseph A. Murray

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Celiac disease is a lifelong disorder for which there is currently only one known, effective treatment: a gluten-free diet. New treatment approaches have recently emerged; several drugs are in Phase 2 trials and results appear promising; however, discussion around regulatory endpoints is in its infancy. We will briefly discuss the drugs that are under development and then shift our attention to potential trial endpoints, such as patient-reported outcomes, histology, serology, gene expression analysis and other tests. We will outline the differing requirements for proof-of-concept Phase 2 trials and Phase 3 registration trials, with a particular emphasis on current thinking in regulatory agencies. We conclude our paper with recommendations and a glossary of regulatory terms, to enable readers who are less familiar with regulatory language to take maximum advantage of this review.

Original languageEnglish (US)
Pages (from-to)91-102
Number of pages12
JournalGastroenterology Report
Issue number2
StatePublished - May 1 2015


  • Celiac disease
  • Clinical trials
  • Endpoints

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Development of drugs for celiac disease: Review of endpoints for Phase 2 and 3 trials'. Together they form a unique fingerprint.

Cite this